This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutInfliximabWhat is infliximabInflammatory Bowel DiseaseMaximising patient outcomes with IBDBiosimilarsWhat is a biosimilarFuture of biosimilarsBiologic switchingINFLECTRA® Introducing INFLECTRA® Position statementsECCOEULARESPGHANDosing & safetyDosingIV dosingAdministration & storageAdministrationStorageSafety informationImportant safety informationConsiderations for SwitchingSwitching to InflectraSafety informationImportant safety informationSafety informationSafety informationClinical evidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceReal-world experienceSummary: real-world evidenceSupporting ResourcesVideosMaterialsPatient Support


Inflectra®(infliximab) Prescribing Information. Adverse events reporting information can be found at the bottom of the page.

 

Introducing INFLECTRA® (CT-P13*/infliximab)

Inflectra/CT-P13* (infliximab) is an approved‡§ biosimilar infliximab.1
 

Demonstrated comparable efficacy and safety profile to Remicade®† in rigorous clinical studies for RA and AS.1-3
 

Via extrapolation, Inflectra is licensed for all of the same therapeutic indications as Remicade®.§,1-3
 

CT-P13* has more than 370,000 patients years of exposure across indications.4
 

Infliximab is a cornerstone treatment for many inflammatory diseases – with more than 15 years of clinical experience across all indications.5-12

INFLECTRA is indicated for the treatment of:Only the IV formulation of infliximab is licensed for paediatric CD and UC3,4​​​​​​​

Return to our Inflectra homepage to explore more about Infliximab 

CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA™.INFLECTRA® (CT-P13/infliximab) infusion therapy has demonstrated comparable efficacy and safety to Remicade™ (infliximab) in rigorous clinical studies for RA and AS and, via extrapolation, has been granted a European Commission licence for all of the same clinical indications as Remicade™.1,3 Guidelines state that “Extrapolation of clinical efficacy and safety data to other indications of the reference mAb, not specifically studied during the clinical development of the biosimilar mAb, is possible based on the results of the overall evidence provided from the comparability exercise and with adequate justification.”1,3Remicade™ is a registered trademark of MSD.AS, Ankylosing spondylitis; CD, Crohn’s disease; mAb, Monoclonal antibody; PsA, Psoriatic arthritis; PsO, Psoriasis; RA, Rheumatoid arthritis; UC, Ulcerative colitis.References:European Public Assessment Report: INFLECTRA®. 27 June 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Public_assessment_report/human/002778/ WC500151490.pdf. Accessed March 2021.INFLECTRA® Summary of Product Characteristics.Guidelines on similar biological medicinal products containing monoclonal antibodies - Non-Clinical Issues [online]. 2012 [viewed: February 2021]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/scientific_guideline/2012/06/WC500128686.pdfIQVIA Cumulative Sales Data. April 2018.Danese S, et al. Aliment PharmacolTher. 2011. 33:857-69Moss AC. Gastroenterol Rep. 2015. 3(1):63-68.FDA. CBER approval letter, infliximab FDA. CBER approval letter, infliximab [online]. 1998[viewed: February 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/inflcen082498L.htmEMA. Public Statement on Remicade® (infliximab).[online]. 2000 [viewed: February 2021] Available at: https://www.ema.europa.eu/en/news/public-statement-remicade-infliximab-reports-tuberculosis-infectionsMedscape [online]. 2005 [viewed: February 2021] Available from@ https://medscape.com/viewarticle/513282EMA. Remicade Scientific Discussion. 2006Centocor, Inc. [Online]. 2007 [viewed: February 2021]. Available from: https://www.eurekalert.org/pub_releases/2007-11/ci-rbf110607.phpRemicade™ Summary of Product Characteristics.
INFLECTRA®
Browse additional content and information that may be of interest to you  Explore MoreLoading
Learn more about Infliximab & important safety information
PP-IFA-GBR-0606. April 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​